US009265775B2

(12) **United States Patent**
Lyons et al.

(10) **Patent No.: US 9,265,775 B2**
(45) **Date of Patent: *Feb. 23, 2016**

(54) **PHARMACEUTICAL COMPOSITIONS**

(71) Applicant: **Allergan, Inc.**, Irvine, CA (US)

(72) Inventors: **Robert T. Lyons**, Laguna Hills, CA (US); **James N. Chang**, Newport Beach, CA (US); **John T. Trogden**, Villa Park, CA (US); **Scott Whitcup**, Laguna Hills, CA (US)

(73) Assignee: **Allergan, Inc.**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/064,960**

(22) Filed: **Oct. 28, 2013**

(65) **Prior Publication Data**

US 2014/0051671 A1 Feb. 20, 2014

Related U.S. Application Data

(60) Continuation of application No. 12/172,194, filed on Jul. 11, 2008, now Pat. No. 8,569,272, which is a division of application No. 10/966,764, filed on Oct. 14, 2004, now abandoned.

(60) Provisional application No. 60/530,062, filed on Dec. 16, 2003, provisional application No. 60/519,237, filed on Nov. 12, 2003.

(51) **Int. Cl.**

A61K 31/58	(2006.01)
A61K 9/00	(2006.01)
A61K 31/573	(2006.01)
A61K 47/36	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/58*** (2013.01); ***A61K 9/0048*** (2013.01); ***A61K 31/573*** (2013.01); ***A61K 47/36*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,396,081	A	8/1968	Billek et al.
3,845,770	A	11/1974	Theeuwes et al.
3,916,899	A	11/1975	Theeuwes et al.
4,008,864	A	2/1977	Torphammar et al.
4,014,335	A	3/1977	Arnold
4,052,505	A	10/1977	Higuchi et al.
4,057,619	A	11/1977	Higuchi et al.
4,063,064	A	12/1977	Saunders et al.
4,088,864	A	5/1978	Theeuwes et al.
4,144,317	A	3/1979	Higuchi et al.
4,158,005	A	6/1979	Bodor et al.
4,186,184	A	1/1980	Zaffaroni
4,190,642	A	2/1980	Gale et al.
4,200,098	A	4/1980	Ayer et al.
4,281,654	A	8/1981	Shell et al.
4,285,987	A	8/1981	Ayer et al.
4,303,637	A	12/1981	Shell et al.
4,304,765	A	12/1981	Shell et al.
4,327,725	A	5/1982	Cortese
4,383,992	A	5/1983	Lipari
4,396,625	A	8/1983	Yamamori et al.
4,425,346	A	1/1984	Horlington et al.
4,474,451	A	10/1984	Mizokami
4,478,818	A	10/1984	Shell et al.
4,494,274	A	1/1985	Thurlow
4,521,210	A	6/1985	Wong
4,599,353	A	7/1986	Bito
4,649,151	A	3/1987	Dougherty et al.
4,656,186	A	4/1987	Bommer et al.
4,668,506	A	5/1987	Bawa
4,675,338	A	6/1987	Bommer et al.
4,693,885	A	9/1987	Bommer et al.
4,712,500	A	12/1987	Montandon
4,713,446	A	12/1987	DeVore et al.
4,727,064	A	2/1988	Pitha
4,853,224	A	8/1989	Wong
4,863,457	A	9/1989	Lee
4,865,846	A	9/1989	Kaufman
4,866,168	A	9/1989	Dougherty et al.
4,920,104	A	4/1990	DeVore et al.
4,932,934	A	6/1990	Dougherty et al.
4,935,498	A	6/1990	Sessler et al.
4,941,874	A	7/1990	Sandow et al.
4,959,217	A	9/1990	Sanders et al.
4,968,715	A	11/1990	Dougherty et al.
4,981,871	A	1/1991	Abelson

(Continued)

FOREIGN PATENT DOCUMENTS

CA	1333770	1/1995
EP	0197718	10/1986

(Continued)

OTHER PUBLICATIONS

Allergan, Alphagan Product Information, Product Sheet, 2005, 1-10.

(Continued)

Primary Examiner — Ernst V Arnold
Assistant Examiner — Kyung Sook Chang
(74) *Attorney, Agent, or Firm* — Brigitte C. Phan; Ted A. Chan

(57) **ABSTRACT**

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

3 Claims, No Drawings